Summary
Within the gp41 glycoprotein of the human immunodeficiency virus type 1 (HIV-1) there is a relatively conserved region which appears accessible to the immune system during the course of HIV infection and is recognised by antibody from virtually all patients with AIDS. This region has also been shown to function as a target for human T cells. We have examined synthetic peptides spanning this sequence, between residues 572 and 604, with a view to evaluating their potential as immunogens. Peptides572GIKQLQARILAVERYLKDQQ591 and579RILAVERYLKDQQLLGGIWGCSGK601 were good immunogens in two different strains of mice while peptide576LQARILAVERYLKDQQ591 was an inferior immunogen, and peptide593LGIWGCSGKLIC604 was non-immunogenic unless coupled to a carrier protein. For both antibody and T cell responses it was apparent that sequences that could function as determinants within one peptide could not do so in the context of a different peptide immunogen. It follows that by judicious choice of immunogen sequence it may be possible to direct the immune response towards a desired fine specificity. Unwanted responses by CD4+ T cells isolated from certain peptide-primed animals were also observed. These T cells showed an unusual reactivity in that they were incapable of recognising their determinant AVERYLKDQQ if it was extended at the C-terminal end with the native sequence and as such would not be expected to recognise the native molecule unless processing created the identical C-terminus.
Article PDF
Similar content being viewed by others
References
Bell SJD, Cooper DA, Kemp BE, Doherty RR, Penny R (1992) Definition of an immunodominant T-cell epitope contained in the envelope gp41 sequence of HIV-1. Clin Exp Immunol 87: 37–45
Berman PW, Gregory TJ, Riddle L, Nakamura GR, Champe MA, Porter JP, Wurm FM, Hershberg RD, Cobbs EK, Eichberg JW (1990) Protection of chimpanzees from infection with HIV-1 after vaccination with recombinant glycoprotein gp120 but not gp160. Nature 345: 622–625
Berzofsky JA, Bensussan A, Cease KB, Bourge JF, Cheynier R, Lurhuma Z, Salaun J-J, Gallo RC, Shearer GM, Zagury D (1988) Antigenic peptides recognized by T lymphocytes from AIDS viral envelope-immune humans. Nature 334: 706–708
Berzofsky JA, Hale PM, Clerici M, Cease KB, Houghten RA, Putney SD, Zajac RA, Boswell RN, Margalit H, Cornette JL, Spouge JL, DeLisi C, Shearer GM (1990) Multideter-minant regions of the HIV-1 envelope with sites seen by murine and human helper T cells: Circumventing the MHC restriction problem. In: Brown F, Chanock RM, Ginsberg H, Lerner RA (eds) Vaccines 90. Cold Spring Harbor Laboratory Press, New York, pp 307–312
Brown LE, Ffrench RA, Gawler JM, Jackson DC, Dyall-Smith ML, Anders EM, Tregear GW, Duncan L, Underwood PA, White DO (1988) Distinct epitopes recognized by I-Ad-restricted T-cell clones within antigenic site E on influenza virus hemagglutinin. J Virol 62: 305–312
Brown LE, Jackson DC, Tribbick G, White DO, Geysen HM (1991) Extension of a minimal T-cell determinant allows relaxation of the requirement for particular residues within the determinant. Int Immunol 3: 1307–1313
Brown LE, Katz JM, Ffrench RA, Anders EM, White DO (1987) Characterization of subtype-specific and cross-reactive helper-T-cell clones recognizing influenza virus hemagglutinin. Cell Immunol 109: 12–24
Cease KB, Margalit H, Cornette JL, Putney SD, Robey WG, Ouyang C, Streicher HZ, Fischinger PJ, Gallo RC, DeLisi C, Berzofsky JA (1987) Helper T-cell antigenic site identification in the acquired immunodeficiency syndrome virus gp120 envelope protein and induction of immunity in mice to the native protein using a 16-residue synthetic peptide. Proc Natl Acad Sci USA 84: 4249–4253
Chanh TC, Dreesman GR, Kanda P, Linette GP, Sparrow JT, Ho DD, Kennedy RC (1986) Induction of anti-HIV neutralizing antibodies by synthetic peptides. EMBO J 5: 3065–3071
Chiengsong-Popov R, Panagiotidi C, Caun K, Klasse PJ, Pipkorn R, Blomberg J, Weber J (1990) Antibodies to a putative HIV gp41 immunosuppressive peptide, PHIVIS (583–599), do not correlate significantly with outcome in HIV infection. AIDS 4: 251–253
Cumming SA, McPhee DA, Maskill WJ, Kemp BE, Doherty RR, Gust ID (1990) Use of a conserved immunodominant epitope of HIV surface glycoprotein gp41 in the detection of early antibodies. AIDS 4: 83–86
Ffrench RA, Tang X-L, Anders EM, Jackson DC, White DO Drummer H, Wade JD, Tregear GW, Brown LE (1989) Class II restricted T-cell clones to a synthetic peptide of influenza virus hemagglutinin differ in their fine specificity and their ability to respond to virus. J Virol 63: 3087–3094
Gallaher WG (1987) Detection of a fusion peptide sequence in the transmembrane protein of human immunodeficiency virus. Cell 50: 327–328
Girard M, Kieny M-P, Pinter A, Barre-Sinoussi F, Nara P, Kolbe H, Kusumi, K, Chaput A, Reinhart T, Muchmore E, Ronco J, Kaczorek M, Gomard E, Gluckman L-C, Fultz PN (1991) Immunization of chimpanzees confers protection against challenge with human immunodeficiency virus. Proc Natl Acad Sci USA 88: 542–546
Gnann JW Jr, McCormick JB, Mitchell S, Nelson JA, Oldstone MBA (1987) Synthetic peptide immunoassay distinguishes HIV type 1 and HIV type 2 infections. Science 237: 1346–1349
Gnann JW, Nelson JA, Oldstone MBA (1987) Fine mapping of an immunodominant domain in the transmembrane glycoprotein. J Virol 61: 2639–2641
Gnann JW, Schwimmbeck PL, Nelson JA, Truax AB, Oldstone MBA (1987) Diagnosis of AIDS by using a 12-amino acid peptide representing an immunodominant epitope of the Human Immunodeficiency Virus. J Infect Dis 156: 261–267
Golding H, Robey FA, Gates TG III, Linder W, Beining PR, Hoffman T, Golding B (1988) Identification of homologous regions in human immunodeficiency virus I gp41 and human MHC class II beta-I domain. J Exp Med 167: 914–923
Good MF, Berzofsky JA, Miller LH (1988) The T-cell response to the malaria circumsporozoite protein: an immunological approach to vaccine development. Annu Rev Immunol 6: 663–668
Goodman-Snitkoff G, Eisele LE, Heimer EP, Felix AM, Andersen TT, Fuerst TR, Mannino RJ (1990) Defining minimal requirements for antibody production to peptide antigens. Vaccine 8: 257–262
Goudsmit J, Debouck C, Meloen RH, Smit L, Bakker M, Asher DM, Wolff AV, Gibbs CJ, Gajdusek DC (1988) Human immunodeficiency virus type 1 neutralization epitope with conserved architecture elicits early type-specific antibodies in experimentally infected chimpanzees. Proc Natl Acad Sci USA 85: 4478–4482
Hammond SA, Obah E, Stanhope P, Monell CR, Strand M, Robbins FM, Bias WB, Karr RW, Koenig S, Siliciano RF (1991) Characterization of a conserved T cell epitope in HIV-1 gp41 recognized by vaccine-induced human cytolytic T cells. J Immunol 146: 1470–1477
Hart MK, Palker TJ, Matthews TJ, Langlois AJ, Lerche NW, Martin ME, Scearce RM, McDanal C, Bolognesi DP, Haynes BF (1990) Synthetic peptides containing B and T cell epitopes from human immunodeficiency virus envelope gp120 induce anti-HIV proliferative responses and high titers of neutralizing antibodies in rhesus monkeys. J Immunol 145: 2677–2685
Ho DD, Sarngadharan MG, Hirsch MS, Schooley RT, Rota TR, Kennedy RC, Chanh TC, Sato V (1987) Human immunodeficiency virus neutralizing antibodies recognize several conserved domains on the envelope glycoproteins. J Virol 61: 2024–2028
Hoffmann B, Langhoff E, Ørskov Lindhart B, Odum N, Hylding-Nielsen JJ, Ryder LP, Platz P, Jakobsen BK, Bendtzen K, Jacobsen N, Lerche B, Schafer-Neilsen C, Dickmeiss E, Ulrich K, Svejgaard A (1989) Investigation of immunosuppressive properties of inactivated human immunodeficiency virus and possible neutralization of this effect by some patient sera. Cell Immunol 121: 336–348
Hosmalin AM, Nara PL, Zweig M, Cease KB, Gard EA, Markham PD, Putney SD, Daniel MD, Desrosiers RC, Berzofsky JA (1989) Enhancement of an antibody response to the envelope glycoprotein of HIV-1 in primates by priming with helper T-cell epitope peptides. In: Lerner RA, Ginsberg H, Chanock RM, Brown F (eds) Vaccines 89. Cold Spring Harbor Laboratory Press, New York, pp 121–124
Johnson RP, Trocha A, Buchanan TM, Walker BD (1992) Identification of overlapping HLA class I-restricted cytotoxic T cell epitopes in a conserved region of the human immunodeficiency virus type 1 envelope glycoprotein: definition of minimum epitopes and analysis of the effects of sequence variation. J Exp Med 175: 961–971
Julius MH, Simpson E, Herzenberg LA (1973) A rapid method for the isolation of functional thymus-derived murine lymphocytes. Eur J Immunol 3: 645–649
Keneally WR, Matthews TJ, Ganfield M-C, Langlois AJ, Waselefsky DM, Petteway SR Jr (1989) Antibodies from human immunodeficiency virus-infected individuals bind to a short amino acid sequence that elicits neutralizing antibodies in animals. AIDS Res Hum Retroviruses 5: 173–182
Kemp BE, Rylatt DB, Bundesen PG, Doherty RR, McPhee DA, Stapleton D, Cottis LE, Wilson K, John MA, Khan JM, Dinh DP, Miles S, Hillyard CJ (1988) Autologous red cell agglutination assay for HIV-1 antibodies: simplified test with whole blood. Science 241: 1352–1354
Klasse PJ, Pipkorn R, Blomberg J (1988) Presence of antibodies to a putatively immunosuppressive part of human immunodeficiency virus (HIV) envelope glycoprotein gp41 is strongly associated with health among HIV-positive subjects. Proc Natl Acad Sci USA 85: 5225–5229
Klasse PJ, Pipkorn, R, Blomberg J (1991) A cluster of continuous antigenic structures in the transmembrane protein of HIV-1: individual patterns of reactivity in human sera. Mol Immunol 28: 613–622
Kowalski M, Potz J, Basiripour L, Dorfman T, Goh WC, Terwilliger E, Dayton A, Rosen C, Haseltine W, Sodroski J (1987) Functional regions of the envelope glycoprotein of human immunodeficiency virus type 1. Science 237: 1351–1355
Lange J, Vahlne A, Dekker J, de Wolf F, Goudsmit J (1989) Antibodies to an HIV-1 synthetic peptide with partial homology to MuLV p15E do not protect against AIDS. AIDS 3: 402–403
Lee ACJ, Powell JE, Tregear GW, Niall HD, Stevens VC (1980) A method for preparing b-hCG COOH peptide-carrier conjugates of predictable composition. Mol Immunol 17: 749–756
Maeji NJ, Bray AM, Geysen HM (1990) Multi-rod peptide synthesis strategy for T cell determinant analysis. J Immunol Methods 134: 23–33
Maskill WJ, Silvester C, Healey (1989) Application of protein blotting to the serodiagnosis of human immunodeficiency virus infection. In: Baldo BA, Tovey ER (eds) Protein blotting. Karger, Basel, pp 69–95
McPhee DA, Cumming SA, Pavuk NC, Doherty RR, Stapleton DI, Kemp BE (1989) Putative contact region between HIV envelope proteins gp120 and gp41: antiviral action of synthetic peptide analogs. In: Lerner RA, Ginsberg H, Chanock RM, Brown F (eds) Vaccines 89. Cold Spring Harbor Laboratory Press, New York, pp 185–189
McPhee DA, Kemp BE, Cumming S, Stapleton D, Gust ID, Doherty RR (1988) Recognition of envelope and tat protein synthetic peptide analogs by HIV positive sera or plasma. FEBS Lett 233: 393–396
Milich DR, Hughes JL, McLachlan A, Thornton GB, Moriarty A (1988) Hepatitis B synthetic immunogen comprised of nucleocapsid T-cell sites and an envelope B-cell epitope. Proc Natl Acad Sci USA 85: 1610–1614
Myer G, Rabson AB, Berzofsky JA, Smith TF, Wong-Staal F (1990) Human retroviruses and AIDS. Theoretical biology and biophysics. Los Alamos, New Mexico
Palker TJ, Clark ME, Langlois AJ, Matthews TJ, Weinhold KJ, Randall RR, Bolognesi DP, Haynes BF (1988) Type-specific neutralization of the human immunodeficiency virus with antibodies to env-encoded synthetic peptides. Proc Natl Acad Sci USA 85: 1932–1936
Palker TJ, Matthews TJ, Langlois A, Tanner ME, Martin ME, Scearce RM, Kim JE, Berzofsky JA, Bolognesi DP, Haynes BF (1989) Polyvalent human immunodeficiency virus synthetic immunogen comprised of envelope gp120 T helper cell sites and B cell neutralization epitopes. J Immunol 142: 3612–3619
Qureshi NM, Coy DH, Garry RF, Henderson LA (1990) Characterization of a putative cellular receptor for HIV-1 transmembrane glycoprotein using synthetic peptides. AIDS 4: 553–558
Reiher WE, Blalock JE, Brunck TK (1986) Sequence homology between acquired immunodeficiency syndrome virus envelope protein and interleukin 2. Proc Natl Acad Sci USA 83: 9188–9192
Rusche JR, Javaherian K, McDanal C, Petro J, Lynn DL, Grimaila R, Langlois A, Gallo RC, Arthur LO, Fischinger PJ, Bolognesi DP, Putney SD, Matthews TJ (1988) Antibodies that inhibit fusion of human immunodeficiency virus-infected cells bind a 24-amino acid sequence of the viral envelope, gp120. Proc Natl Acad Sci USA 85: 3198–3202
Sattentau QJ, Moore JP (1991) Conformational changes induced in the human immunodeficiency virus envelope glycoprotein by soluble CD4 binding. J Exp Med 174: 407–415
Schrier RD, Gnann JW, Langlois AJ, Shriver K, Nelson JA, Oldstone MBA (1988) B-and T-lymphocyte responses to an immunodominant epitope of human immunodeficiency virus. J Virol 62: 2531–2536
Smith RS, Naso RB, Rosen J, Whalley A, Hom Y-L, Hoey K, Kennedy CJ, McCutchan JA, Spector SA, Richman DD (1987) Antibody to a synthetic oligopeptide in subjects at risk for human immunodeficiency virus infection. J Clin Microbiol 25: 1498–1504
Tang X-L, Tregear GW, White DO, Jackson DC (1988) Minimum requirements for immunogenic and antigenic activities of homologs of a synthetic peptide of influenza virus hemagglutinin. J Virol 62: 4745–4751
Wang JJG, Steel S, Wisniewolski R, Wang CY (1986) Detection of antibodies to human T-lymphotrophic virus type III by using a synthetic peptide of 21 amino acid residues corresponding to a highly antigenic segment of gp41 envelope protein. Proc Natl Acad Sci USA 83: 6159–6163
Wild C, Oas T, McDanal C, Bolognesi D, Matthews T (1992) A synthetic peptide inhibitor of human immunodeficiency virus replication: correlation between solution structure and viral inhibition. Proc Natl Acad Sci USA 89: 10537–10541
Xu J-Y, Gorny MK, Palker T, Karwowska S, Zolla-Pazner S (1991) Epitope mapping of two immunodominant domains of gp41, the transmembrane protein of human immunodeficiency virus type 1, using ten human monoclonal antibodies. J Virol 65: 4832–4838
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Brown, L.E., White, D.O., Agius, C. et al. Synthetic peptides representing sequences within gp41 of HIV as immunogens for murine T- and B-cell responses. Archives of Virology 140, 635–654 (1995). https://doi.org/10.1007/BF01309955
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF01309955